A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Latest Information Update: 17 Dec 2021
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms CENTERA
- Sponsors Bayer
- 01 Jul 2021 Primary endpoint (The Proportion of Participants With a Mean Treatment Interval Between Injections of 8 Weeks) has not been met, as per results published in the American Journal of Ophthalmology.
- 01 Jul 2021 Primary endpoint (The Proportion of Participants Who Gained 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline) has been met, as per results published in the American Journal of Ophthalmology.
- 01 Jul 2021 Results published in the American Journal of Ophthalmology